How to manage toxicities from Immune Checkpoint Inhibitors?

Patients treated with Immune checkpoint inhibitors like anti-CTLA-4, anti-PD-1 and anti-PD-L1 drugs, may develop immune-related adverse events. As any tissue can be involved, it is very important to recognize these side effects early and manage them promptly and effectively to get the best outcome for the patients.
In this educational video of the 'How To' series, John Haanen explains how to manage immunotherapy induced colitis, hepatitis and pneumonitis.
Download the full ESMO Guidelines Slides Set:
www.esmo.org/Guidelines/ESMO-...
Produced by the European Society for Medical Oncology
www.esmo.org